CRDL
NASDAQ · Pharmaceuticals
Cardiol Therapeutics Inc-A
$1.05
+0.06 (+5.54%)
Financial Highlights (FY 2025)
Revenue
21.47M
Net Income
5.10M
Gross Margin
32.1%
Profit Margin
23.8%
Rev Growth
+3.9%
D/E Ratio
1.16
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 32.1% | 32.1% | 32.1% |
| Operating Margin | 36.5% | 39.5% | 35.1% |
| Profit Margin | 23.8% | 26.0% | 27.3% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 21.47M | 20.00M | 18.14M |
| Gross Profit | 6.90M | 6.43M | 5.83M |
| Operating Income | 7.84M | 7.91M | 6.37M |
| Net Income | 5.10M | 5.20M | 4.96M |
| Gross Margin | 32.1% | 32.1% | 32.1% |
| Operating Margin | 36.5% | 39.5% | 35.1% |
| Profit Margin | 23.8% | 26.0% | 27.3% |
| Rev Growth | +3.9% | -4.2% | -9.3% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 64.11M | 70.42M | 60.03M |
| Total Equity | 55.27M | 55.09M | 60.24M |
| D/E Ratio | 1.16 | 1.28 | 1.00 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 10.24M | 10.30M | 9.42M |
| Free Cash Flow | 5.58M | 6.38M | 6.16M |